Advanced Search

Project: Drug Therapy for Early Rheumatoid Arthritis in Adults: A Systematic Review Update

Public Report Complete



Project Summary

Title and Description


Key Questions



Associated Studies (each link opens a new tab)

Title Author Year
Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Bijlsma JWJ., Welsing PMJ., Woodworth TG., Middelink LM., Pethö-Schramm A., Bernasconi C., Borm MEA., Wortel CH., Ter Borg EJ., Jahangier ZN., van der Laan WH., Bruyn GAW., Baudoin P., Wijngaarden S., Vos PAJM., Bos R., Starmans MJF., Griep EN., Griep-Wentink JRM., Allaart CF., Heurkens AHM., Teitsma XM., Tekstra J., Marijnissen ACA., Lafeber FPJ., Jacobs JWG. 2016
Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial. Porter D., van Melckebeke J., Dale J., Messow CM., McConnachie A., Walker A., Munro R., McLaren J., McRorie E., Packham J., Buckley CD., Harvie J., Taylor P., Choy E., Pitzalis C., McInnes IB. 2016
Long-Term Outcomes of Patients With Recent-Onset Rheumatoid Arthritis After 10 Years of Tight Controlled Treatment: A Randomized Trial. Markusse IM., Akdemir G., Dirven L., Goekoop-Ruiterman YP., van Groenendael JH., Han KH., Molenaar TH., Le Cessie S., Lems WF., van der Lubbe PA., Kerstens PJ., Peeters AJ., Ronday HK., de Sonnaville PB., Speyer I., Stijnen T., Ten Wolde S., Huizinga TW., Allaart CF. 2016
Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study). Heimans L., Akdemir G., Boer KV., Goekoop-Ruiterman YP., Molenaar ET., van Groenendael JH., Peeters AJ., Steup-Beekman GM., Lard LR., de Sonnaville PB., Grillet BA., Huizinga TW., Allaart CF. 2016
Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial. Kuusalo L., Puolakka K., Kautiainen H., Blåfield H., Eklund KK., Ilva K., Kaipiainen-Seppänen O., Karjalainen A., Korpela M., Valleala H., Leirisalo-Repo M., Rantalaiho V. 2015
The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Atsumi T., Yamamoto K., Takeuchi T., Yamanaka H., Ishiguro N., Tanaka Y., Eguchi K., Watanabe A., Origasa H., Yasuda S., Yamanishi Y., Kita Y., Matsubara T., Iwamoto M., Shoji T., Okada T., van der Heijde D., Miyasaka N., Koike T. 2016
Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE). Smolen JS., Wollenhaupt J., Gomez-Reino JJ., Grassi W., Gaillez C., Poncet C., Le Bars M., Westhovens R. 2015
Existing joint erosions increase the risk of joint space narrowing independently of clinical synovitis in patients with early rheumatoid arthritis. Landewé R., Smolen JS., Florentinus S., Chen S., Guérette B., van der Heijde D. 2015
Predicted vs. observed radiographic progression in early rheumatoid arthritis (POPeRA): results from a randomized trial. Levitsky A., Forslind K., van Vollenhoven RF. 2015
Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial. Verschueren P., De Cock D., Corluy L., Joos R., Langenaken C., Taelman V., Raeman F., Ravelingien I., Vandevyvere K., Lenaerts J., Geens E., Geusens P., Vanhoof J., Durnez A., Remans J., Vander Cruyssen B., Van Essche E., Sileghem A., De Brabanter G., Joly J., Van der Elst K., Meyfroidt S., Westhovens R. 2015
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Emery P., Burmester GR., Bykerk VP., Combe BG., Furst DE., Barré E., Karyekar CS., Wong DA., Huizinga TW. 2015
Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial. Verschueren P., De Cock D., Corluy L., Joos R., Langenaken C., Taelman V., Raeman F., Ravelingien I., Vandevyvere K., Lenaerts J., Geens E., Geusens P., Vanhoof J., Durnez A., Remans J., Vander Cruyssen B., Van Essche E., Sileghem A., De Brabanter G., Joly J., Meyfroidt S., Van der Elst K., Westhovens R. 2015
Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis. Markusse IM., de Vries-Bouwstra JK., Han KH., van der Lubbe PA., Schouffoer AA., Kerstens PJ., Lems WF., Huizinga TW., Allaart CF. 2014
When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET). Dougados MR., van der Heijde DM., Brault Y., Koenig AS., Logeart IS. 2014
Rheumatoid factor and anti-CCP do not predict progressive joint damage in patients with early rheumatoid arthritis treated with prednisolone: a randomised study. Hafström I., Engvall IL., Rönnelid J., Boonen A., van der Heijde D., Svensson B. 2014
Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial. ter Wee MM., den Uyl D., Boers M., Kerstens P., Nurmohamed M., van Schaardenburg D., Voskuyl AE., Lems WF. 2015
Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. de Jong PH., Hazes JM., Han HK., Huisman M., van Zeben D., van der Lubbe PA., Gerards AH., van Schaeybroeck B., de Sonnaville PB., van Krugten MV., Luime JJ., Weel AE. 2014
Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. Ajeganova S., Svensson B., Hafström I. 2014
Health-related quality of life and functional ability in patients with early arthritis during remission steered treatment: results of the IMPROVED study. Heimans L., Wevers-de Boer KV., Koudijs KK., Visser K., Goekoop-Ruiterman YP., Harbers JB., Steup-Beekman GM., Lard LR., Grillet BA., Huizinga TW., Allaart CF. 2013
Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial. Yamanaka H., Ishiguro N., Takeuchi T., Miyasaka N., Mukai M., Matsubara T., Uchida S., Akama H., Kupper H., Arora V., Tanaka Y. 2014
A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Axelsen MB., Eshed I., Hørslev-Petersen K., Stengaard-Pedersen K., Hetland ML., Møller J., Junker P., Pødenphant J., Schlemmer A., Ellingsen T., Ahlquist P., Lindegaard H., Linauskas A., Dam MY., Hansen I., Horn HC., Ammitzbøll CG., Jørgensen A., Krintel SB., Raun J., Krogh NS., Johansen JS., Østergaard M. 2015
Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension. Keystone EC., Breedveld FC., van der Heijde D., Landewé R., Florentinus S., Arulmani U., Liu S., Kupper H., Kavanaugh A. 2014
Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial. Smolen JS., Emery P., Fleischmann R., van Vollenhoven RF., Pavelka K., Durez P., Guérette B., Kupper H., Redden L., Arora V., Kavanaugh A. 2014
M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis. Ammitzbøll CG., Thiel S., Jensenius JC., Ellingsen T., Hørslev-Petersen K., Hetland ML., Junker P., Krogh NS., Østergaard M., Stengaard-Pedersen K. 2013
Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Nam JL., Villeneuve E., Hensor EM., Conaghan PG., Keen HI., Buch MH., Gough AK., Green MJ., Helliwell PS., Keenan AM., Morgan AW., Quinn M., Reece R., van der Heijde DM., Wakefield RJ., Emery P. 2014
Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial. Rantalaiho V., Kautiainen H., Korpela M., Hannonen P., Kaipiainen-Seppänen O., Möttönen T., Kauppi M., Karjalainen A., Laiho K., Laasonen L., Hakola M., Peltomaa R., Leirisalo-Repo M. 2014
Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial. Eriksson JK., Neovius M., Bratt J., Petersson IF., van Vollenhoven RF., Geborek P., Ernestam S. 2013
A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Heimans L., Wevers-de Boer KV., Visser K., Goekoop RJ., van Oosterhout M., Harbers JB., Bijkerk C., Speyer I., de Buck MP., de Sonnaville PB., Grillet BA., Huizinga TW., Allaart CF. 2014
Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. O'Dell JR., Curtis JR., Mikuls TR., Cofield SS., Bridges SL., Ranganath VK., Moreland LW. 2013
A non-inferiority trial of an attenuated combination strategy ('COBRA-light') compared to the original COBRA strategy: clinical results after 26 weeks. den Uyl D., ter Wee M., Boers M., Kerstens P., Voskuyl A., Nurmohamed M., Raterman H., van Schaardenburg D., van Dillen N., Dijkmans B., Lems W. 2014
Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Hørslev-Petersen K., Hetland ML., Junker P., Pødenphant J., Ellingsen T., Ahlquist P., Lindegaard H., Linauskas A., Schlemmer A., Dam MY., Hansen I., Horn HC., Ammitzbøll CG., Jørgensen A., Krintel SB., Raun J., Johansen JS., Østergaard M., Stengaard-Pedersen K. 2014
Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study. Takeuchi T., Yamanaka H., Ishiguro N., Miyasaka N., Mukai M., Matsubara T., Uchida S., Akama H., Kupper H., Arora V., Tanaka Y. 2014
Risk of alanine transferase (ALT) elevation in patients with rheumatoid arthritis treated with methotrexate in a DAS-steered strategy. Dirven L., Klarenbeek NB., van den Broek M., van Groenendael JH., de Sonnaville PB., Kerstens PJ., Huizinga TW., Dijkmans BA., Lems WF., Allaart CF. 2013
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. Karlsson JA., Neovius M., Nilsson JÅ., Petersson IF., Bratt J., van Vollenhoven RF., Ernestam S., Geborek P. 2013
Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate. Smolen JS., van der Heijde DM., Keystone EC., van Vollenhoven RF., Goldring MB., Guérette B., Cifaldi MA., Chen N., Liu S., Landewé RB. 2013
Prevalence of vertebral fractures in a disease activity steered cohort of patients with early active rheumatoid arthritis. Dirven L., van den Broek M., van Groenendael JH., de Beus WM., Kerstens PJ., Huizinga TW., Allaart CF., Lems WF. 2012
Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study). Leirisalo-Repo M., Kautiainen H., Laasonen L., Korpela M., Kauppi MJ., Kaipiainen-Seppänen O., Luosujärvi R., Luukkainen R., Karjalainen A., Blåfield H., Uutela T., Ilva K., Julkunen HA., Paimela L., Puolakka K., Moilanen E., Hannonen PJ., Möttönen T. 2013
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Detert J., Bastian H., Listing J., Weiß A., Wassenberg S., Liebhaber A., Rockwitz K., Alten R., Krüger K., Rau R., Simon C., Gremmelsbacher E., Braun T., Marsmann B., Höhne-Zimmer V., Egerer K., Buttgereit F., Burmester GR. 2013
Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. de Jong PH., Hazes JM., Barendregt PJ., Huisman M., van Zeben D., van der Lubbe PA., Gerards AH., de Jager MH., de Sonnaville PB., Grillet BA., Luime JJ., Weel AE. 2013
Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Montecucco C., Todoerti M., Sakellariou G., Scirè CA., Caporali R. 2012
Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Kavanaugh A., Fleischmann RM., Emery P., Kupper H., Redden L., Guerette B., Santra S., Smolen JS. 2013
A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Moreland LW., O'Dell JR., Paulus HE., Curtis JR., Bathon JM., St Clair EW., Bridges SL., Zhang J., McVie T., Howard G., van der Heijde D., Cofield SS. 2012
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. van Vollenhoven RF., Geborek P., Forslind K., Albertsson K., Ernestam S., Petersson IF., Chatzidionysiou K., Bratt J. 2012
Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Bakker MF., Jacobs JW., Welsing PM., Verstappen SM., Tekstra J., Ton E., Geurts MA., van der Werf JH., van Albada-Kuipers GA., Jahangier-de Veen ZN., van der Veen MJ., Verhoef CM., Lafeber FP., Bijlsma JW. 2012
Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. Strand V., Rentz AM., Cifaldi MA., Chen N., Roy S., Revicki D. 2012
Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Tak PP., Rigby W., Rubbert-Roth A., Peterfy C., van Vollenhoven RF., Stohl W., Healy E., Hessey E., Reynard M., Shaw T. 2012
Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. Wells AF., Westhovens R., Reed DM., Fanti L., Becker JC., Covucci A., Keystone EC. 2011
Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Bathon J., Robles M., Ximenes AC., Nayiager S., Wollenhaupt J., Durez P., Gomez-Reino J., Grassi W., Haraoui B., Shergy W., Park SH., Genant H., Peterfy C., Becker JC., Covucci A., Moniz Reed D., Helfrick R., Westhovens R. 2011
Does achieving clinical response prevent work stoppage or work absence among employed patients with early rheumatoid arthritis? Zhang W., Sun H., Emery P., Sato R., Singh A., Freundlich B., Anis AH. 2012
Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Rigby W., Ferraccioli G., Greenwald M., Zazueta-Montiel B., Fleischmann R., Wassenberg S., Ogale S., Armstrong G., Jahreis A., Burke L., Mela C., Chen A. 2011
The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Klarenbeek NB., Güler-Yüksel M., van der Kooij SM., Han KH., Ronday HK., Kerstens PJ., Seys PE., Huizinga TW., Dijkmans BA., Allaart CF. 2011
Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Klarenbeek NB., van der Kooij SM., Güler-Yüksel M., van Groenendael JH., Han KH., Kerstens PJ., Huizinga TW., Dijkmans BA., Allaart CF. 2011
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Tak PP., Rigby WF., Rubbert-Roth A., Peterfy CG., van Vollenhoven RF., Stohl W., Hessey E., Chen A., Tyrrell H., Shaw TM. 2011
Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER. van der Heijde D., Breedveld FC., Kavanaugh A., Keystone EC., Landewé R., Patra K., Pangan AL. 2010
Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis. Cummins L., Katikireddi VS., Shankaranarayana S., Su KY., Duggan E., Videm V., Pahau H., Thomas R. 2015
Tumor necrosis factor α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis. Bili A., Tang X., Pranesh S., Bozaite R., Morris SJ., Antohe JL., Kirchner HL., Wasko MC. 2014
Baseline factors predicting change from the initial DMARD treatment during the first 2 years of rheumatoid arthritis: experience in the ERAN inception cohort. McWilliams DF., Kiely PD., Young A., Walsh DA. 2013
Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA. Lie E., Uhlig T., van der Heijde D., Rødevand E., Kalstad S., Kaufmann C., Mikkelsen K., Kvien TK. 2012
Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study. Kellner H., Bornholdt K., Hein G. 2010
Treatment of early RA in clinical practice: a comparative study of two different DMARD/corticosteroid options. Svensson B., Ahlmén M., Forslind K. -- Not Found --
Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. Todoerti M., Scirè CA., Boffini N., Bugatti S., Montecucco C., Caporali R. 2010
Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Rantalaiho V., Korpela M., Laasonen L., Kautiainen H., Järvenpää S., Hannonen P., Leirisalo-Repo M., Blåfield H., Puolakka K., Karjalainen A., Möttönen T. 2010
Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial. Karstila KL., Rantalaiho VM., Mustonen JT., Möttönen TT., Hannonen PJ., Leirisalo-Repo M., Kaipiainen-Seppänen OA., Karjalainen AH., Korpela MM. -- Not Found --
Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial. Rezaei H., Saevarsdottir S., Geborek P., Petersson IF., van Vollenhoven RF., Forslind K. 2013
Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Allaart CF., Goekoop-Ruiterman YP., de Vries-Bouwstra JK., Breedveld FC., Dijkmans BA. -- Not Found --
Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. Klarenbeek NB., van der Kooij SM., Huizinga TJ., Goekoop-Ruiterman YP., Hulsmans HM., van Krugten MV., Speyer I., de Vries-Bouwstra JK., Kerstens PJ., Huizinga TW., Dijkmans BA., Allaart CF. 2010
Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Emery P., Breedveld F., van der Heijde D., Ferraccioli G., Dougados M., Robertson D., Pedersen R., Koenig AS., Freundlich B. 2010
Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Kekow J., Moots RJ., Emery P., Durez P., Koenig A., Singh A., Pedersen R., Robertson D., Freundlich B., Sato R. 2010
Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. van Tuyl LH., Boers M., Lems WF., Landewé RB., Han H., van der Linden S., van de Laar M., Westhovens R., van Denderen JC., Westedt ML., Peeters AJ., Jacobs P., Huizinga TW., van de Brink H., Dijkmans BA., Voskuyl AE. 2010
Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial. Rantalaiho VM., Kautiainen H., Korpela M., Hannonen PJ., Leirisalo-Repo M., Möttönen T. 2013
Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial. Ørnbjerg LM., Østergaard M., Jensen T., Hørslev-Petersen K., Stengaard-Pedersen K., Junker P., Ellingsen T., Ahlquist P., Lindegaard H., Linauskas A., Schlemmer A., Dam MY., Hansen I., Lottenburger T., Ammitzbøll CG., Jørgensen A., Krintel SB., Raun J., Hetland ML., Slot O., Nielsen LK., Skjødt H., Majgaard O., Lorenzen T., Horn HC., Kowalski M., Johansen IL., Pedersen PM., Manilo N., Bliddal H. 2017
Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial. Verschueren P., De Cock D., Corluy L., Joos R., Langenaken C., Taelman V., Raeman F., Ravelingien I., Vandevyvere K., Lenaerts J., Geens E., Geusens P., Vanhoof J., Durnez A., Remans J., Vander Cruyssen B., Van Essche E., Sileghem A., De Brabanter G., Joly J., Meyfroidt S., Van der Elst K., Westhovens R. 2017
Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial. Eriksson JK., Wallman JK., Miller H., Petersson IF., Ernestam S., Vivar N., van Vollenhoven RF., Neovius M. 2016
Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA). Hørslev-Petersen K., Hetland ML., Ørnbjerg LM., Junker P., Pødenphant J., Ellingsen T., Ahlquist P., Lindegaard H., Linauskas A., Schlemmer A., Dam MY., Hansen I., Lottenburger T., Ammitzbøll CG., Jørgensen A., Krintel SB., Raun J., Johansen JS., Østergaard M., Stengaard-Pedersen K. 2016
Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexate. Emery P., Smolen JS., Ganguli A., Meerwein S., Bao Y., Kupper H., Chen N., Kavanaugh A. 2016
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Conaghan PG., Østergaard M., Bowes MA., Wu C., Fuerst T., van der Heijde D., Irazoque-Palazuelos F., Soto-Raices O., Hrycaj P., Xie Z., Zhang R., Wyman BT., Bradley JD., Soma K., Wilkinson B. 2016
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Burmester GR., Rigby WF., van Vollenhoven RF., Kay J., Rubbert-Roth A., Kelman A., Dimonaco S., Mitchell N. 2016
Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial. Kuijper TM., Luime JJ., de Jong PH., Gerards AH., van Zeben D., Tchetverikov I., de Sonnaville PB., van Krugten MV., Grillet BA., Hazes JM., Weel AE. 2016
Adherence to methotrexate in rheumatoid arthritis: a danish nationwide cohort study. Bliddal H., Eriksen SA., Christensen R., Lorenzen T., Hansen MS., Østergaard M., Dreyer L., Luta G., Vestergaard P. 2015
Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. Bathon JM., Fleischmann RM., Van der Heijde D., Tesser JR., Peloso PM., Chon Y., White B. 2006
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. Bathon JM., Martin RW., Fleischmann RM., Tesser JR., Schiff MH., Keystone EC., Genovese MC., Wasko MC., Moreland LW., Weaver AL., Markenson J., Finck BK. 2000
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Boers M., Verhoeven AC., Markusse HM., van de Laar MA., Westhovens R., van Denderen JC., van Zeben D., Dijkmans BA., Peeters AJ., Jacobs P., van den Brink HR., Schouten HJ., van der Heijde DM., Boonen A., van der Linden S. 1997
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Breedveld FC., Weisman MH., Kavanaugh AF., Cohen SB., Pavelka K., van Vollenhoven R., Sharp J., Perez JL., Spencer-Green GT. 2006
Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. Genovese MC., Bathon JM., Fleischmann RM., Moreland LW., Martin RW., Whitmore JB., Tsuji WH., Leff JA. 2005
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Genovese MC., Bathon JM., Martin RW., Fleischmann RM., Tesser JR., Schiff MH., Keystone EC., Wasko MC., Moreland LW., Weaver AL., Markenson J., Cannon GW., Spencer-Green G., Finck BK. 2002
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Goekoop-Ruiterman YP., de Vries-Bouwstra JK., Allaart CF., van Zeben D., Kerstens PJ., Hazes JM., Zwinderman AH., Ronday HK., Han KH., Westedt ML., Gerards AH., van Groenendael JH., Lems WF., van Krugten MV., Breedveld FC., Dijkmans BA. 2005
COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Landewé RB., Boers M., Verhoeven AC., Westhovens R., van de Laar MA., Markusse HM., van Denderen JC., Westedt ML., Peeters AJ., Dijkmans BA., Jacobs P., Boonen A., van der Heijde DM., van der Linden S. 2002
Infliximab treatment maintains employability in patients with early rheumatoid arthritis. Smolen JS., Han C., van der Heijde D., Emery P., Bathon JM., Keystone E., Kalden JR., Schiff M., Bala M., Baker D., Han J., Maini RN., St Clair EW. 2006
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. St Clair EW., van der Heijde DM., Smolen JS., Maini RN., Bathon JM., Emery P., Keystone E., Schiff M., Kalden JR., Wang B., Dewoody K., Weiss R., Baker D. 2004
Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Svensson B., Boonen A., Albertsson K., van der Heijde D., Keller C., Hafström I. 2005
Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Puolakka K., Kautiainen H., Möttönen T., Hannonen P., Korpela M., Julkunen H., Luukkainen R., Vuori K., Paimela L., Blåfield H., Hakala M., Leirisalo-Repo M. 2004
Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Korpela M., Laasonen L., Hannonen P., Kautiainen H., Leirisalo-Repo M., Hakala M., Paimela L., Blåfield H., Puolakka K., Möttönen T. 2004
Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study. Maillefert JF., Combe B., Goupille P., Cantagrel A., Dougados M. 2003
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Dougados M., Combe B., Cantagrel A., Goupille P., Olive P., Schattenkirchner M., Meusser S., Paimela L., Rau R., Zeidler H., Leirisalo-Repo M., Peldan K. 1999
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Möttönen T., Hannonen P., Leirisalo-Repo M., Nissilä M., Kautiainen H., Korpela M., Laasonen L., Julkunen H., Luukkainen R., Vuori K., Paimela L., Blåfield H., Hakala M., Ilva K., Yli-Kerttula U., Puolakka K., Järvinen P., Hakola M., Piirainen H., Ahonen J., Pälvimäki I., Forsberg S., Koota K., Friman C. 1999
Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Haagsma CJ., van Riel PL., de Jong AJ., van de Putte LB. 1997
Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. van der Kooij SM., de Vries-Bouwstra JK., Goekoop-Ruiterman YP., Ewals JA., Han KH., Hazes JM., Kerstens PJ., Peeters AJ., van Zeben D., Breedveld FC., Huizinga TW., Dijkmans BA., Allaart CF. 2009
Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Bejarano V., Quinn M., Conaghan PG., Reece R., Keenan AM., Walker D., Gough A., Green M., McGonagle D., Adebajo A., Jarrett S., Doherty S., Hordon L., Melsom R., Unnebrink K., Kupper H., Emery P. 2008
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. van der Kooij SM., Goekoop-Ruiterman YP., de Vries-Bouwstra JK., Güler-Yüksel M., Zwinderman AH., Kerstens PJ., van der Lubbe PA., de Beus WM., Grillet BA., Ronday HK., Huizinga TW., Breedveld FC., Dijkmans BA., Allaart CF. 2009
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Emery P., Breedveld FC., Hall S., Durez P., Chang DJ., Robertson D., Singh A., Pedersen RD., Koenig AS., Freundlich B. 2008
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Smolen JS., Han C., van der Heijde DM., Emery P., Bathon JM., Keystone E., Maini RN., Kalden JR., Aletaha D., Baker D., Han J., Bala M., St Clair EW. 2009
Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. Kimel M., Cifaldi M., Chen N., Revicki D. 2008
Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. Choy EH., Smith CM., Farewell V., Walker D., Hassell A., Chau L., Scott DL. 2008
Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Goekoop-Ruiterman YP., de Vries-Bouwstra JK., Allaart CF., van Zeben D., Kerstens PJ., Hazes JM., Zwinderman AH., Peeters AJ., de Jonge-Bok JM., Mallée C., de Beus WM., de Sonnaville PB., Ewals JA., Breedveld FC., Dijkmans BA. 2007
Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score. van der Kooij SM., Goekoop-Ruiterman YP., de Vries-Bouwstra JK., Peeters AJ., van Krugten MV., Breedveld FC., Dijkmans BA., Allaart CF. 2008
The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. Anis A., Zhang W., Emery P., Sun H., Singh A., Freundlich B., Sato R. 2009
Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add? Schipper LG., Fransen J., Barrera P., den Broeder AA., Van Riel PL. 2009
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. van Vollenhoven RF., Ernestam S., Geborek P., Petersson IF., Cöster L., Waltbrand E., Zickert A., Theander J., Thörner A., Hellström H., Teleman A., Dackhammar C., Akre F., Forslind K., Ljung L., Oding R., Chatzidionysiou A., Wörnert M., Bratt J. 2009
Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Hafström I., Albertsson K., Boonen A., van der Heijde D., Landewé R., Svensson B. 2009
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Westhovens R., Robles M., Ximenes AC., Nayiager S., Wollenhaupt J., Durez P., Gomez-Reino J., Grassi W., Haraoui B., Shergy W., Park SH., Genant H., Peterfy C., Becker JC., Covucci A., Helfrick R., Bathon J. 2009
Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Quinn MA., Conaghan PG., O'Connor PJ., Karim Z., Greenstein A., Brown A., Brown C., Fraser A., Jarret S., Emery P. 2005
Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Burmester GR., Rigby WF., van Vollenhoven RF., Kay J., Rubbert-Roth A., Blanco R., Kadva A., Dimonaco S. 2017
Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Atsumi T., Tanaka Y., Yamamoto K., Takeuchi T., Yamanaka H., Ishiguro N., Eguchi K., Watanabe A., Origasa H., Yasuda S., Yamanishi Y., Kita Y., Matsubara T., Iwamoto M., Shoji T., Togo O., Okada T., van der Heijde D., Miyasaka N., Koike T. 2017
Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost-utility analysis of the tREACH trial. de Jong PH., Hazes JM., Buisman LR., Barendregt PJ., van Zeben D., van der Lubbe PA., Gerards AH., de Jager MH., de Sonnaville PB., Grillet BA., Luime JJ., Weel AE. 2016
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Emery P., Bingham CO., Burmester GR., Bykerk VP., Furst DE., Mariette X., van der Heijde D., van Vollenhoven R., Arendt C., Mountian I., Purcaru O., Tatla D., VanLunen B., Weinblatt ME. 2017
Rheumatoid Arthritis and Risk of Malignant Lymphoma: Is the Risk Still Increased? Hellgren K., Baecklund E., Backlin C., Sundstrom C., Smedby KE., Askling J. 2017
Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial. Levitsky A., Brismar K., Hafström I., Hambardzumyan K., Lourdudoss C., van Vollenhoven RF., Saevarsdottir S. 2017
Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Durez P., Malghem J., Nzeusseu Toukap A., Depresseux G., Lauwerys BR., Westhovens R., Luyten FP., Corluy L., Houssiau FA., Verschueren P. 2007
Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Marcora SM., Chester KR., Mittal G., Lemmey AB., Maddison PJ. 2006
Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Soubrier M., Puéchal X., Sibilia J., Mariette X., Meyer O., Combe B., Flipo RM., Mulleman D., Berenbaum F., Zarnitsky C., Schaeverbeke T., Fardellone P., Dougados M. 2009
Sustained remission and reduced radiographic progression with combination disease modifying antirheumatic drugs in early rheumatoid arthritis. Mäkinen H., Kautiainen H., Hannonen P., Möttönen T., Leirisalo-Repo M., Laasonen L., Korpela M., Blåfield H., Hakola M., Sokka T. 2007
Janssen Response to Data Requested by the Agency for Healthcare Research and Quality on Drug Therapy for Early Rheumatoid Arthritis in Adults An Update Janssen Research and Development LLC 2017
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-nave Adults With Early Active Rheumatoid Arthritis (C-early) UCB Pharma SA 2012
Patient-reported outcomes in newly diagnosed early rheumatoid arthritis patients treated to target with a tocilizumab- or methotrexate-based strategy. Teitsma XM., Jacobs JWG., Welsing PMJ., Pethö-Schramm A., Borm MEA., Hendriks L., Denissen NHAM., van Laar JM., Lafeber FPJG., Bijlsma JWJ. 2017




Creative Commons LicenseThis graphic notice indicates that you are leaving this Federal Government Web site and entering a non-Federal Web site. Creative Commons  
The data contained in this project are distributed under the terms of the Creative Commons Attribution-NonCommerical license, which permits the use, dissemination, and reproduction in any medium, provided the original work is properly cited, and that the use is non-commercial and otherwise in compliance with the license. See: https://creativecommons.org/licenses/by-nc/3.0/